ARTICLE SUMMARY:
In this week’s Pathways Picks: Breakthrough devices will lose streamlined path to add-on payments, and more Medicare updates; FDA details MDUFA VI user fee amounts; UK defines when an AI scribe is a medical device; registering trials in Canada; and more global medical policy updates.
[Editor’s note: Pathways Picks will not be published next week. Look out for a new edition on August 19.]
CMS Tightens NTAP Access, With Transition
Products under development via FDA’s Breakthrough Device Program will have two more years to try to qualify for new technology Medicare bonus payments without meeting the high bar of “substantial clinical improvement” (SCI) compared to existing treatments. After that, FDA Breakthrough Devices seeking new-technology add-on payments (NTAPs) or outpatient device pass-through payments must meet the same clinical standards as all other products, CMS said July 31 in the FY 2027 hospital inpatient prospective payment system (IPPS) rule. In the proposed version, the agency said it would cancel the “alternative pathway” for breakthrough devices starting next year, but in the final regulation it agreed to honor the streamlined, no-SCI standard route for FY 2028 and 2029 for devices that gain a breakthrough designation by September 30, 2026 and FDA authorization by May 1, 2028. (For more see, “CMS Stands Firm On Tightening NTAP Access, But Grants Two-Year Transition.”)